Pregled bibliografske jedinice broj: 273729
Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients : two therapeutic protocols compared
Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients : two therapeutic protocols compared // Nephron. Clinical practice, 103 (2006), 1; C8-C11 doi:10.1159/000090505 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 273729 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients : two therapeutic protocols compared
Autori
Grgurević, Ivica ; Vince, Adriana ; Buljevac, Mladen ; Banić, Marko ; Jeren-Strujić, Branka ; Kes, Petar ; Kujundžić, Milan ; Leko, Ninoslav ; Lukić, Ivan Krešimir ; Slavićek, Jasna
Izvornik
Nephron. Clinical practice (1660-2110) 103
(2006), 1;
C8-C11
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
interferon alpha; chronic hepatitis C; dyalisis
(nterferon alpha; chronic hepatitis C; dyalisis)
Sažetak
Data on the efficacy of particular therapeutic protocols of interferon-alpha (IFN-alpha) treatment for chronic hepatitis C in patients on hemodialysis (HD) vary. AIim was to compare the efficacy of two different therapeutic protocols for HD patients. 15 hepatitis C virus (HCV)-positive patients on chronic HD at two dialysis centers: 8 patients treated with IFN-alpha 3 x 3 MU/week s.c. for 6 months (group A), and 7 patients treated with IFN-alpha 3 x 5 MU/week for 3 months, then 1 x 5 MU/week for another 3 months (group B). End of treatment response (ETR) and sustained virologic response (SVR) were evaluated by HCV-RNA determination. There was no statistically significant difference between the two patient groups according to age, sex, duration of HD and HCV infection. ETR was 87.5% (7/8) in group A and 28.5% (2/7) in group B, being statistically significant (p < 0.05). Although better SVR [50% (4/8) vs. 28.5% (2/7)] and lower drop-out rate [0% (0/8) vs. 28.5% (2/7)] were achieved in group A compared to group B, these differences did not reach statistical significance (p > 0.05). Therapy with IFN-alpha 3 x 3 MU/week s.c. for 6 months seems to be more appropriate for treatment of hepatitis C in HD patients, mostly due to better tolerability, i.e. lower drop-out rate. These differences could be attributed to different pharmacokinetic properties of the particular therapy protocol. 2006 S. Karger AG, Basel
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
0143001
Ustanove:
Klinika za infektivne bolesti "Dr Fran Mihaljević"
Profili:
Branka Jeren-Strujić
(autor)
Mladen Buljevac
(autor)
Adriana Vince
(autor)
Ivica Grgurević
(autor)
Petar Kes
(autor)
Marko Banić
(autor)
Ivan Krešimir Lukić
(autor)
Milan Kujundžić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- BIOSIS Previews (Biological Abstracts)
- EMBASE (Excerpta Medica)